Altimmune (ALT) Financials

$5.61 +0.12 (+2.19%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$5.60 0.00 (-0.09%)

As of 04:40 AM Eastern

Annual Income Statements for Altimmune

This table shows Altimmune's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-95	-88	-85
Consolidated Net Income / (Loss)	-95	-88	-85
Net Income / (Loss) Continuing Operations	-95	-88	-85
Total Pre-Tax Income	-95	-88	-85
Total Operating Income	-103	-96	-88
Total Gross Profit	0.02	0.43	-0.07
Total Revenue	0.02	0.43	-0.07
Operating Revenue	0.02	0.43	-0.07
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	103	96	88
Selling, General & Admin Expense	21	18	17
Research & Development Expense	82	66	71
Impairment Charge	0.00	12	0.00
Total Other Income / (Expense), net	8.11	7.48	2.83
Interest Expense	0.01	0.04	0.01
Interest & Investment Income	8.07	7.35	2.87
Other Income / (Expense), net	0.05	0.17	-0.03
Basic Earnings per Share	($1.34)	($1.66)	($1.81)
Weighted Average Basic Shares Outstanding	71.00M	53.25M	46.93M
Diluted Earnings per Share	($1.34)	($1.66)	($1.81)
Weighted Average Diluted Shares Outstanding	71.00M	53.25M	46.93M
Weighted Average Basic & Diluted Shares Outstanding	77.01M	70.90M	49.28M

This table shows Altimmune's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-23	-23	-25	-24	-32	-21	-16	-20	-22	-24
Consolidated Net Income / (Loss)	-23	-23	-25	-24	-32	-21	-16	-20	-22	-24
Net Income / (Loss) Continuing Operations	-23	-23	-25	-24	-32	-21	-16	-20	-22	-24
Total Pre-Tax Income	-72	-23	0.00	0.00	-68	-21	0.00	0.00	-22	-24
Total Operating Income	-25	-25	-27	-27	-34	-23	-18	-22	-23	-25
Total Gross Profit	0.01	0.01	0.01	0.01	0.04	0.36	0.01	0.02	-0.11	0.00
Total Revenue	0.01	0.01	0.01	0.01	0.04	0.36	0.01	0.02	-0.11	0.00
Operating Revenue	0.01	0.01	0.01	0.01	0.04	0.36	0.01	0.02	-	-
Total Operating Expenses	25	25	27	27	34	23	18	22	23	25
Selling, General & Admin Expense	5.09	4.97	5.60	5.31	4.33	4.51	4.76	4.53	3.81	4.49
Research & Development Expense	20	20	21	21	17	18	13	17	19	20
Total Other Income / (Expense), net	1.69	1.92	2.11	2.40	1.98	1.87	1.95	1.69	1.43	1.04
Interest & Investment Income	1.57	1.91	2.18	2.41	1.96	1.88	1.84	1.67	1.47	1.05
Other Income / (Expense), net	0.12	0.02	-0.08	-0.01	0.02	0.01	0.11	0.02	-0.22	0.05
Basic Earnings per Share	($0.33)	($0.32)	($0.35)	($0.34)	($0.55)	($0.39)	($0.32)	($0.40)	($0.47)	($0.48)
Weighted Average Basic Shares Outstanding	71.00M	71.08M	70.92M	70.80M	53.25M	53.63M	50.69M	50.13M	46.93M	49.29M
Diluted Earnings per Share	($0.33)	($0.32)	($0.35)	($0.34)	($0.55)	($0.39)	($0.32)	($0.40)	($0.47)	($0.48)
Weighted Average Diluted Shares Outstanding	71.00M	71.08M	70.92M	70.80M	53.25M	53.63M	50.69M	50.13M	46.93M	49.29M
Weighted Average Basic & Diluted Shares Outstanding	77.01M	71.12M	71.07M	70.90M	70.90M	53.73M	52.69M	49.29M	49.28M	49.16M

This table details how cash moves in and out of Altimmune's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-98	24	-79
Net Cash From Operating Activities	-80	-76	-63
Net Cash From Continuing Operating Activities	-80	-76	-63
Net Income / (Loss) Continuing Operations	-95	-88	-85
Consolidated Net Income / (Loss)	-95	-88	-85
Depreciation Expense	0.24	0.48	0.49
Amortization Expense	-3.85	-2.47	-0.70
Non-Cash Adjustments To Reconcile Net Income	14	23	8.14
Changes in Operating Assets and Liabilities, net	4.48	-8.27	14
Net Cash From Investing Activities	-28	14	-73
Net Cash From Continuing Investing Activities	-28	14	-73
Purchase of Property, Plant & Equipment	0.00	-0.05	-0.13
Purchase of Investments	-116	-89	-73
Sale and/or Maturity of Investments	87	102	0.00
Net Cash From Financing Activities	10	86	57
Net Cash From Continuing Financing Activities	10	86	57
Issuance of Common Equity	10	87	56
Other Financing Activities, net	-0.25	-0.71	0.43

This table details how cash moves in and out of Altimmune's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	5.45	-26	-22	-56	48	-15	-2.33	-6.41	-16	-8.39
Net Cash From Operating Activities	-18	-27	-18	-16	-17	-20	-19	-19	-17	-15
Net Cash From Continuing Operating Activities	-18	-27	-18	-16	-17	-20	-19	-19	-17	-15
Net Income / (Loss) Continuing Operations	-23	-23	-25	-24	-32	-21	-16	-20	-22	-24
Consolidated Net Income / (Loss)	-23	-23	-25	-24	-32	-21	-16	-20	-22	-24
Depreciation Expense	0.03	0.04	0.06	0.11	0.11	0.12	0.12	0.13	0.46	-0.14
Amortization Expense	-0.82	-0.98	-1.07	-0.98	-0.70	-0.67	-0.63	-0.48	-	-
Non-Cash Adjustments To Reconcile Net Income	3.24	3.07	4.38	3.66	15	2.71	2.67	2.66	2.11	2.08
Changes in Operating Assets and Liabilities, net	2.46	-6.40	3.16	5.26	0.82	-1.97	-5.49	-1.63	2.48	6.53
Net Cash From Investing Activities	14	1.20	-3.70	-40	-7.96	4.40	3.99	13	0.98	-25
Net Cash From Continuing Investing Activities	14	1.20	-3.70	-40	-7.96	4.40	3.99	13	0.98	-25
Purchase of Investments	-13	-26	-23	-54	-34	-12	-22	-21	1.02	-25
Sale and/or Maturity of Investments	27	27	20	14	26	16	26	35	-	-
Net Cash From Financing Activities	10	0.27	-0.05	-0.26	73	0.59	13	-0.30	-0.04	32
Net Cash From Continuing Financing Activities	10	0.27	-0.05	-0.26	73	0.59	13	-0.30	-0.04	32
Issuance of Common Equity	9.99	0.13	-	0.17	73	0.59	13	0.14	-	32
Other Financing Activities, net	0.09	0.14	-0.05	-0.43	0.02	-0.00	-0.29	-0.44	-0.04	0.16

This table presents Altimmune's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	139	211	207
Total Current Assets	137	210	193
Cash & Equivalents	37	135	111
Restricted Cash	0.04	0.04	0.03
Short-Term Investments	95	63	74
Accounts Receivable	0.54	1.11	0.17
Prepaid Expenses	2.20	6.92	5.36
Other Current Assets	2.57	3.74	2.37
Plant, Property, & Equipment, net	0.41	0.65	1.08
Total Noncurrent Assets	1.64	0.36	13
Other Noncurrent Operating Assets	1.64	0.36	0.62
Total Liabilities & Shareholders' Equity	139	211	207
Total Liabilities	16	17	22
Total Current Liabilities	10	12	17
Accounts Payable	0.21	2.07	4.80
Accrued Expenses	10	10	12
Total Noncurrent Liabilities	5.33	4.40	4.58
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	124	194	185
Total Preferred & Common Equity	124	194	185
Total Common Equity	124	194	185
Common Stock	690	665	568
Retained Earnings	-561	-466	-378
Accumulated Other Comprehensive Income / (Loss)	-4.97	-5.00	-5.23

This table presents Altimmune's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	148	173	188	167	183	187	225
Total Current Assets	146	171	188	153	170	173	211
Cash & Equivalents	31	57	79	87	102	105	127
Restricted Cash	0.04	0.04	0.04	0.04	0.04	0.03	0.03
Short-Term Investments	108	108	103	54	58	61	74
Accounts Receivable	0.43	0.42	0.31	0.88	0.14	0.25	0.63
Prepaid Expenses	3.00	3.23	2.87	7.62	5.82	3.98	4.79
Other Current Assets	2.91	2.59	2.27	3.65	3.58	3.12	3.72
Plant, Property, & Equipment, net	0.45	0.48	0.54	0.77	0.88	1.01	1.17
Total Noncurrent Assets	1.66	1.68	0.30	13	13	13	13
Other Noncurrent Operating Assets	1.66	1.68	0.30	0.43	0.48	0.55	0.68
Total Liabilities & Shareholders' Equity	148	173	188	167	183	187	225
Total Liabilities	14	21	15	16	16	19	20
Total Current Liabilities	8.64	15	11	12	11	15	16
Accounts Payable	1.13	2.69	3.76	3.05	4.04	5.24	1.42
Accrued Expenses	7.51	12	7.57	8.83	7.40	9.71	14
Total Noncurrent Liabilities	5.85	5.66	4.09	4.31	4.17	4.40	4.51
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	133	153	173	150	168	168	205
Total Preferred & Common Equity	133	153	173	150	168	168	205
Total Common Equity	133	153	173	150	168	168	205
Common Stock	676	673	669	590	587	571	567
Retained Earnings	-538	-515	-491	-435	-414	-398	-356
Accumulated Other Comprehensive Income / (Loss)	-4.85	-5.19	-5.16	-5.12	-5.18	-5.10	-5.30

This table displays calculated financial ratios and metrics derived from Altimmune's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-95.31%	726.47%	-101.54%
EBITDA Growth	-9.19%	-11.12%	9.06%
EBIT Growth	-7.69%	-9.10%	9.78%
NOPAT Growth	-7.55%	-9.33%	9.47%
Net Income Growth	-7.48%	-4.41%	12.75%
EPS Growth	19.28%	8.29%	22.98%
Operating Cash Flow Growth	-5.33%	-21.13%	20.01%
Free Cash Flow Firm Growth	-9.00%	-25.58%	30.93%
Invested Capital Growth	-582.84%	-87.08%	-69.65%
Revenue Q/Q Growth	-61.54%	52.69%	-102.05%
EBITDA Q/Q Growth	7.50%	-15.49%	0.45%
EBIT Q/Q Growth	7.91%	-12.04%	0.85%
NOPAT Q/Q Growth	7.82%	-12.33%	1.01%
Net Income Q/Q Growth	8.17%	-12.72%	2.56%
EPS Q/Q Growth	14.10%	-5.06%	4.74%
Operating Cash Flow Q/Q Growth	-2.22%	1.01%	6.93%
Free Cash Flow Firm Q/Q Growth	-6.55%	4.78%	14.91%
Invested Capital Q/Q Growth	-1,479.08%	-95.38%	-35.37%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	0.00%
EBITDA Margin	-533,680.00%	-22,947.65%	0.00%
Operating Margin	-515,860.00%	-22,518.54%	0.00%
EBIT Margin	-515,620.00%	-22,479.58%	0.00%
Profit (Net Income) Margin	-475,295.00%	-20,762.21%	0.00%
Tax Burden Percent	100.00%	100.00%	99.77%
Interest Burden Percent	92.18%	92.36%	96.74%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,397.80%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,386.40%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,351.17%	0.00%
Return on Equity (ROE)	-59.86%	-46.63%	-44.07%
Cash Return on Invested Capital (CROIC)	0.00%	-2,243.57%	-469.71%
Operating Return on Assets (OROA)	-58.94%	-45.87%	0.00%
Return on Assets (ROA)	-54.33%	-42.36%	0.00%
Return on Common Equity (ROCE)	-59.86%	-46.63%	-44.07%
Return on Equity Simple (ROE_SIMPLE)	-76.97%	-45.57%	-45.72%
Net Operating Profit after Tax (NOPAT)	-72	-67	-61
NOPAT Margin	-361,102.00%	-15,762.98%	0.00%
Net Nonoperating Expense Percent (NNEP)	-14.27%	-11.40%	-12.83%
Return On Investment Capital (ROIC_SIMPLE)	-58.47%	-34.60%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	104,830.00%	4,257.51%	0.00%
R&D to Revenue	411,130.00%	15,445.77%	0.00%
Operating Expenses to Revenue	515,960.00%	22,618.54%	0.00%
Earnings before Interest and Taxes (EBIT)	-103	-96	-88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-107	-98	-88
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.15	3.11	4.36
Price to Tangible Book Value (P/TBV)	4.15	3.11	4.68
Price to Revenue (P/Rev)	25,640.43	1,418.90	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	634.31	125.76
Enterprise Value to Revenue (EV/Rev)	19,043.78	954.45	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.01	-0.99	-0.94
Leverage Ratio	1.10	1.10	1.11
Compound Leverage Factor	1.02	1.02	1.07
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	12.48	18.45	19.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	13.11	17.26	11.31
Quick Ratio	12.65	16.38	10.85
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-68	-63	-50
Operating Cash Flow to CapEx	0.00%	-161,297.87%	-49,671.43%
Free Cash Flow to Firm to Interest Expense	-7,609.38	-1,795.18	-6,254.25
Operating Cash Flow to Interest Expense	-8,872.00	-2,166.00	-7,823.25
Operating Cash Flow Less CapEx to Interest Expense	-8,872.00	-2,167.34	-7,839.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.02	0.66	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.04	0.49	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	15,101.88	550.07	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	15,101.88	550.07	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-3.10	0.64	4.96
Invested Capital Turnover	-0.02	0.15	0.00
Increase / (Decrease) in Invested Capital	-3.74	-4.32	-11
Enterprise Value (EV)	381	407	624
Market Capitalization	513	604	809
Book Value per Share	$1.74	$3.61	$3.77
Tangible Book Value per Share	$1.74	$3.61	$3.52
Total Capital	124	194	185
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-132	-198	-185
Capital Expenditures (CapEx)	0.00	0.05	0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.15	-0.37	-9.16
Debt-free Net Working Capital (DFNWC)	127	197	176
Net Working Capital (NWC)	127	197	176
Net Nonoperating Expense (NNE)	23	21	23
Net Nonoperating Obligations (NNO)	-127	-193	-180
Total Depreciation and Amortization (D&A)	-3.61	-1.99	-0.21
Debt-free, Cash-free Net Working Capital to Revenue	-25,735.00%	-87.56%	0.00%
Debt-free Net Working Capital to Revenue	633,930.00%	46,357.51%	0.00%
Net Working Capital to Revenue	633,930.00%	46,357.51%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.34)	($1.66)	($1.81)
Adjusted Weighted Average Basic Shares Outstanding	71.00M	53.25M	46.93M
Adjusted Diluted Earnings per Share	($1.34)	($1.66)	($1.81)
Adjusted Weighted Average Diluted Shares Outstanding	71.00M	53.25M	46.93M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.01M	70.90M	49.28M
Normalized Net Operating Profit after Tax (NOPAT)	-72	-58	-61
Normalized NOPAT Margin	-361,102.00%	-13,722.30%	0.00%
Pre Tax Income Margin	-475,295.00%	-20,762.21%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-11,458.22	-2,736.09	-10,971.50
NOPAT to Interest Expense	-8,024.49	-1,918.58	-7,677.25
EBIT Less CapEx to Interest Expense	-11,458.22	-2,737.43	-10,987.25
NOPAT Less CapEx to Interest Expense	-8,024.49	-1,919.92	-7,693.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Altimmune's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-86.49%	-98.62%	-16.67%	-76.19%	133.64%	18,000.00%	-25.00%	-34.38%	-103.36%	-98.73%
EBITDA Growth	25.30%	-11.32%	-51.25%	-25.28%	-49.61%	7.10%	9.44%	-14.67%	4.58%	25.18%
EBIT Growth	26.35%	-9.87%	-49.89%	-23.30%	-44.15%	8.81%	12.16%	-12.13%	3.13%	26.24%
NOPAT Growth	26.04%	-9.88%	-48.53%	-23.14%	-45.59%	8.94%	11.71%	-11.59%	3.71%	25.45%
Net Income Growth	26.74%	-10.52%	-53.42%	-21.52%	-46.08%	12.10%	20.12%	-3.31%	9.33%	29.82%
EPS Growth	40.00%	17.95%	-9.38%	15.00%	-17.02%	18.75%	23.81%	9.09%	16.07%	40.74%
Operating Cash Flow Growth	-10.48%	-32.37%	6.58%	15.72%	4.47%	-36.13%	-16.04%	-43.48%	21.22%	15.33%
Free Cash Flow Firm Growth	28.86%	85.18%	99.40%	31.56%	-301.88%	-56.05%	-2,477.72%	-270.34%	77.64%	64.18%
Invested Capital Growth	-582.84%	-101.41%	-156.87%	-179.13%	-87.08%	80.90%	5.44%	-41.38%	-69.65%	-29.67%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-86.49%	-89.78%	5,933.33%	-71.43%	119.09%	-5,600.00%	-75.00%
EBITDA Q/Q Growth	0.61%	7.68%	-0.53%	12.71%	-48.12%	-25.43%	16.73%	3.30%	8.03%	-22.28%
EBIT Q/Q Growth	0.00%	7.73%	-0.06%	20.23%	-49.17%	-25.89%	17.69%	6.74%	5.63%	-21.27%
NOPAT Q/Q Growth	-0.40%	7.40%	0.18%	20.31%	-49.17%	-25.17%	17.24%	5.78%	6.70%	-21.36%
Net Income Q/Q Growth	-1.47%	7.28%	-1.01%	22.90%	-53.07%	-28.70%	19.99%	7.32%	7.89%	-16.95%
EPS Q/Q Growth	-3.13%	8.57%	-2.94%	38.18%	-41.03%	-21.88%	20.00%	14.89%	2.08%	-14.29%
Operating Cash Flow Q/Q Growth	32.65%	-49.76%	-10.70%	1.06%	19.30%	-5.70%	0.12%	-12.14%	-14.99%	9.90%
Free Cash Flow Firm Q/Q Growth	-319.47%	-3,999.25%	98.92%	61.77%	12.59%	-66.34%	-23.13%	-124.50%	66.06%	-2,647.64%
Invested Capital Q/Q Growth	-1,479.08%	97.10%	-34.09%	-886.27%	-95.38%	16.81%	86.59%	28.41%	-35.37%	-31.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%
EBITDA Margin	-510,680.00%	-513,820.00%	-556,580.00%	-553,640.00%	-92,389.19%	-6,375.14%	-306,650.00%	-105,219.05%	0.00%	-1,242,150.00%
Operating Margin	-497,320.00%	-495,340.00%	-534,900.00%	-535,880.00%	-90,872.97%	-6,226.52%	-300,116.67%	-103,614.29%	0.00%	-1,237,600.00%
EBIT Margin	-494,960.00%	-494,980.00%	-536,420.00%	-536,120.00%	-90,818.92%	-6,222.65%	-298,233.33%	-103,523.81%	0.00%	-1,235,100.00%
Profit (Net Income) Margin	-463,600.00%	-456,900.00%	-492,800.00%	-487,880.00%	-85,516.22%	-5,710.22%	-267,683.33%	-95,590.48%	0.00%	-1,175,800.00%
Tax Burden Percent	32.10%	100.00%	0.00%	0.00%	46.68%	100.00%	0.00%	0.00%	100.00%	99.17%
Interest Burden Percent	291.80%	92.31%	0.00%	0.00%	201.70%	91.77%	0.00%	0.00%	92.92%	96.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,634.86%	-59,751.02%	-231,448.55%	-9,676.24%	-112.83%	0.00%	0.00%	0.00%	-309,420.06%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,630.79%	-59,747.27%	-231,445.22%	-9,671.91%	-109.90%	0.00%	0.00%	0.00%	-309,416.93%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,503.91%	58,790.92%	230,542.32%	9,529.12%	103.23%	0.00%	0.00%	0.00%	295,536.48%
Return on Equity (ROE)	-59.86%	-130.96%	-960.10%	-906.23%	-147.12%	-9.60%	-44.89%	-48.42%	-44.07%	-13,883.58%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-2,243.57%	-612.25%	-535.02%	-678.94%	-469.71%	-632.81%
Operating Return on Assets (OROA)	-56.58%	-163.71%	-1,230.27%	-1,170.94%	-185.31%	-8.86%	0.00%	0.00%	0.00%	-17,738.82%
Return on Assets (ROA)	-52.99%	-151.12%	-1,130.23%	-1,065.58%	-174.49%	-8.13%	0.00%	0.00%	0.00%	-16,887.14%
Return on Common Equity (ROCE)	-59.86%	-130.96%	-960.10%	-906.23%	-147.12%	-9.60%	-44.89%	-48.42%	-44.07%	-13,883.58%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-77.61%	-66.44%	-53.64%	0.00%	-52.17%	-48.48%	-50.89%	0.00%	-42.40%
Net Operating Profit after Tax (NOPAT)	-17	-17	-19	-19	-24	-16	-13	-15	-16	-17
NOPAT Margin	-348,124.00%	-346,738.00%	-374,430.00%	-375,116.00%	-63,611.08%	-4,358.56%	-210,081.67%	-72,530.00%	0.00%	-866,320.00%
Net Nonoperating Expense Percent (NNEP)	-3.61%	-4.08%	-3.76%	-3.32%	-4.34%	-2.93%	-2.04%	-2.89%	-3.03%	-3.13%
Return On Investment Capital (ROIC_SIMPLE)	-14.09%	-	-	-	-12.13%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	101,800.00%	99,380.00%	111,900.00%	106,240.00%	11,708.11%	1,246.96%	79,333.33%	21,576.19%	0.00%	224,600.00%
R&D to Revenue	395,620.00%	396,060.00%	423,100.00%	429,740.00%	45,700.00%	5,079.56%	220,883.33%	82,138.10%	0.00%	1,013,100.00%
Operating Expenses to Revenue	497,420.00%	495,440.00%	535,000.00%	535,980.00%	90,972.97%	6,326.52%	300,216.67%	103,714.29%	0.00%	1,237,700.00%
Earnings before Interest and Taxes (EBIT)	-25	-25	-27	-27	-34	-23	-18	-22	-23	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	-26	-28	-28	-34	-23	-18	-22	-23	-25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.15	3.27	3.09	4.17	3.11	0.91	1.04	1.24	4.36	3.02
Price to Tangible Book Value (P/TBV)	4.15	3.27	3.09	4.17	3.11	0.99	1.12	1.34	4.68	3.22
Price to Revenue (P/Rev)	25,640.43	8,391.84	1,152.81	1,760.28	1,418.90	490.98	0.00	0.00	0.00	186.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	634.31	0.03	1.53	7.32	125.76	55.05
Enterprise Value to Revenue (EV/Rev)	19,043.78	5,710.65	749.51	1,316.22	954.45	1.68	0.00	0.00	0.00	127.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.02	0.03	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.02	0.03	0.00	0.02
Financial Leverage	-1.01	-0.95	-0.98	-1.00	-0.99	-0.94	-0.94	-0.95	-0.94	-0.96
Leverage Ratio	1.10	1.11	1.11	1.10	1.10	1.10	1.09	1.11	1.11	1.12
Compound Leverage Factor	3.22	1.02	0.00	0.00	2.22	1.01	0.00	0.00	1.03	1.07
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	2.78%	2.42%	2.56%	0.00%	2.15%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	2.78%	2.42%	2.56%	0.00%	2.15%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	97.22%	97.58%	97.44%	100.00%	97.85%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.05	-0.05	-0.05	0.00	-0.05
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	1.61	1.79	1.80	0.00	2.23
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.05	-0.05	-0.05	0.00	-0.05
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.07	-0.07	-0.07	0.00	-0.07
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	2.28	2.54	2.56	0.00	3.18
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.07	-0.07	-0.07	0.00	-0.07
Altman Z-Score	14.34	13.54	10.00	25.09	19.43	2.00	4.24	4.10	20.52	16.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.11	16.87	11.30	16.55	17.26	12.89	14.82	11.58	11.31	13.40
Quick Ratio	12.65	16.19	10.91	16.09	16.38	11.93	14.00	11.10	10.85	12.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-3.26	-0.08	-7.35	-19	-22	-13	-11	-4.78	-14
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-38,052.94%	-45,542.11%	-25,083.33%
Free Cash Flow to Firm to Interest Expense	0.00	-543.15	0.00	-7,346.80	0.00	-758.14	0.00	-5,367.65	0.00	-220.14
Operating Cash Flow to Interest Expense	0.00	-4,519.67	0.00	-16,357.00	0.00	-706.45	0.00	-9,703.50	0.00	-235.16
Operating Cash Flow Less CapEx to Interest Expense	0.00	-4,519.67	0.00	-16,357.00	0.00	-706.45	0.00	-9,729.00	0.00	-236.09
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Accounts Receivable Turnover	0.02	0.08	1.46	1.47	0.66	0.37	0.00	0.00	0.00	3.01
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.04	0.09	0.60	0.53	0.49	0.29	0.00	0.00	0.00	1.13
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	15,101.88	4,576.54	249.88	248.82	550.07	987.07	0.00	0.00	0.00	121.34
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	15,101.88	4,576.54	249.88	248.82	550.07	987.07	0.00	0.00	0.00	121.34
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.10	-0.20	-6.76	-5.04	0.64	14	12	6.37	4.96	7.67
Invested Capital Turnover	-0.02	0.01	0.16	0.62	0.15	0.03	0.00	0.00	0.00	0.36
Increase / (Decrease) in Invested Capital	-3.74	-14	-19	-11	-4.32	6.21	0.61	-4.50	-11	-3.24
Enterprise Value (EV)	381	297	307	540	407	0.47	18	47	624	422
Market Capitalization	513	436	471	722	604	137	174	208	809	620
Book Value per Share	$1.74	$1.88	$2.15	$2.44	$3.61	$2.85	$3.40	$3.40	$3.77	$4.22
Tangible Book Value per Share	$1.74	$1.88	$2.15	$2.44	$3.61	$2.62	$3.15	$3.15	$3.52	$3.97
Total Capital	124	133	153	173	194	155	172	172	185	210
Total Debt	0.00	0.00	0.00	0.00	0.00	4.31	4.17	4.40	0.00	4.51
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	4.31	4.17	4.40	0.00	4.51
Net Debt	-132	-139	-165	-182	-198	-137	-156	-161	-185	-197
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	-0.00	0.05	0.04	0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.15	-2.30	-8.92	-5.88	-0.37	0.27	-1.90	-7.60	-9.16	-6.60
Debt-free Net Working Capital (DFNWC)	127	137	156	176	197	141	158	158	176	195
Net Working Capital (NWC)	127	137	156	176	197	141	158	158	176	195
Net Nonoperating Expense (NNE)	5.77	5.51	5.92	5.64	8.10	4.89	3.46	4.84	5.49	6.19
Net Nonoperating Obligations (NNO)	-127	-134	-159	-178	-193	-137	-156	-161	-180	-197
Total Depreciation and Amortization (D&A)	-0.79	-0.94	-1.01	-0.88	-0.58	-0.55	-0.51	-0.36	0.46	-0.14
Debt-free, Cash-free Net Working Capital to Revenue	-25,735.00%	-4,425.00%	-2,180.44%	-1,434.88%	-87.56%	97.85%	0.00%	0.00%	0.00%	-198.82%
Debt-free Net Working Capital to Revenue	633,930.00%	263,694.23%	38,149.39%	42,971.22%	46,357.51%	50,570.97%	0.00%	0.00%	0.00%	5,883.16%
Net Working Capital to Revenue	633,930.00%	263,694.23%	38,149.39%	42,971.22%	46,357.51%	50,570.97%	0.00%	0.00%	0.00%	5,883.16%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.32)	($0.35)	($0.34)	($0.55)	($0.39)	($0.32)	($0.40)	($0.47)	($0.48)
Adjusted Weighted Average Basic Shares Outstanding	71.00M	71.08M	70.92M	70.80M	53.25M	53.63M	50.69M	50.13M	46.93M	49.29M
Adjusted Diluted Earnings per Share	($0.33)	($0.32)	($0.35)	($0.34)	($0.55)	($0.39)	($0.32)	($0.39)	($0.47)	($0.48)
Adjusted Weighted Average Diluted Shares Outstanding	71.00M	71.08M	70.92M	70.80M	53.25M	53.63M	50.69M	50.13M	46.93M	49.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.01M	71.12M	71.07M	70.90M	70.90M	53.73M	52.69M	49.29M	49.28M	49.16M
Normalized Net Operating Profit after Tax (NOPAT)	-17	-17	-19	-19	-24	-16	-13	-15	-16	-17
Normalized NOPAT Margin	-348,124.00%	-346,738.00%	-374,430.00%	-375,116.00%	-63,611.08%	-4,358.56%	-210,081.67%	-72,530.00%	0.00%	-866,320.00%
Pre Tax Income Margin	-1,444,280.00%	-456,900.00%	0.00%	0.00%	-183,178.38%	-5,710.22%	0.00%	0.00%	0.00%	-1,185,650.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-4,124.83	0.00	-26,806.00	0.00	-776.76	0.00	-10,870.00	0.00	-385.97
NOPAT to Interest Expense	0.00	-2,889.48	0.00	-18,755.80	0.00	-544.07	0.00	-7,615.65	0.00	-270.73
EBIT Less CapEx to Interest Expense	0.00	-4,124.83	0.00	-26,806.00	0.00	-776.76	0.00	-10,895.50	0.00	-386.91
NOPAT Less CapEx to Interest Expense	0.00	-2,889.48	0.00	-18,755.80	0.00	-544.07	0.00	-7,641.15	0.00	-271.66
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Altimmune's Financials

When does Altimmune's fiscal year end?

According to the most recent income statement we have on file, Altimmune's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Altimmune's net income changed over the last 2 years?

Altimmune's net income appears to be on an upward trend, with a most recent value of -$95.06 million in 2024, rising from -$84.71 million in 2022. The previous period was -$88.45 million in 2023. View Altimmune's forecast to see where analysts expect Altimmune to go next.

What is Altimmune's operating income?

Altimmune's total operating income in 2024 was -$103.17 million, based on the following breakdown:

Total Gross Profit: $20 thousand
Total Operating Expenses: $103.19 million

How has Altimmune revenue changed over the last 2 years?

Over the last 2 years, Altimmune's total revenue changed from -$68 thousand in 2022 to $20 thousand in 2024, a change of -129.4%.

How much debt does Altimmune have?

Altimmune's total liabilities were at $15.80 million at the end of 2024, a 4.5% decrease from 2023, and a 27.0% decrease since 2022.

How much cash does Altimmune have?

In the past 2 years, Altimmune's cash and equivalents has ranged from $36.93 million in 2024 to $135.12 million in 2023, and is currently $36.93 million as of their latest financial filing in 2024.

How has Altimmune's book value per share changed over the last 2 years?

Over the last 2 years, Altimmune's book value per share changed from 3.77 in 2022 to 1.74 in 2024, a change of -53.9%.

Related Companies

This page (NASDAQ:ALT) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Financials

Frequently Asked Questions About Altimmune's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Financials

Annual Income Statements for Altimmune

Quarterly Income Statements for Altimmune

Annual Cash Flow Statements for Altimmune

Quarterly Cash Flow Statements for Altimmune

Annual Balance Sheets for Altimmune

Quarterly Balance Sheets for Altimmune

Annual Metrics And Ratios for Altimmune

Quarterly Metrics And Ratios for Altimmune

Frequently Asked Questions About Altimmune's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools